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Background. D-tagatose is an isomer of fructose and is ~90% as sweet as sucrose with less caloric value. Nowadays, D-tagatose is
used as a nutritive or low-calorie sweetener. Despite clinical findings suggesting that D-tagatose could be beneficial in subjects
with type 2 diabetes, there are no experimental data comparing D-tagatose with fructose, in terms of metabolic derangements
and related molecular mechanisms evoked by chronic exposure to these two monosaccharides. Materials and methods. C57Bl/6j
mice were fed with a control diet plus water (CD), a control diet plus 30% fructose syrup (L-Fr), a 30% fructose solid diet plus
water (S-Fr), a control diet plus 30% D-tagatose syrup (L-Tg), or a 30% D-tagatose solid diet plus water (S-Tg), during 24
weeks. Results. Both solid and liquid fructose feeding led to increased body weight, abnormal systemic glucose homeostasis, and
an altered lipid profile. These effects were associated with vigorous increase in oxidative markers. None of these metabolic
abnormalities were detected when mice were fed with both the solid and liquid D-tagatose diets, either at the systemic or at the
local level. Interestingly, both fructose formulations led to significant Advanced Glycation End Products (AGEs) accumulation
in mouse hearts, as well as a robust increase in both myocardial AGE receptor (RAGE) expression and NF-κB activation. In
contrast, no toxicological effects were shown in hearts of mice chronically exposed to liquid or solid D-tagatose. Conclusion. Our
results clearly suggest that chronic overconsumption of D-tagatose in both formulations, liquid or solid, does not exert the same
deleterious metabolic derangements evoked by fructose administration, due to differences in carbohydrate interference with
selective proinflammatory and oxidative stress cascades.
1. Introduction
Excess of sugar consumption has been linked epidemiolog-
ically with the development of cardiometabolic diseases
[1–4]. Among the most widely added sugars used, fructose
has been a source of great concern, according to several stud-
ies showing that high-fructose intake is a main driver of a
whole range of metabolic and cardiovascular alterations in
animal and human models [5]. High dietary fructose intake
promotes the development of pathological characteristics
leading to obesity, insulin resistance, and type 2 diabetes
[6, 7]. Epidemiologic evidence has been confirmed by several
experimental data, showing that consumption of high
fructose in beverages causes metabolic syndrome phenotype
in rodents [8]. However, the mechanism through which
excessive fructose intake causes dysmetabolic effects is not
completely known. Fructose is absorbed in the small intestine
by specific facilitative transporters expressed in both the api-
cal and basolateral membrane of enterocytes. After absorp-
tion, fructose is primarily metabolized in the liver, which
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takes up at least 50% of the initial fructose flux. We have con-
tributed to deepen the molecular mechanisms leading to the
peculiar lipid deposition induced by excessive fructose con-
sumption in ectopic tissues, such as the liver and skeletal
muscle. Specifically, we showed that the high chemical reac-
tivity of fructose substantially contributes to the massive for-
mation of intracellular Advanced Glycation End Products
(AGEs), thus evoking marked cellular alterations and organ
dysfunction [9–14]. More recently, we documented that con-
sumption of different fructose formulations, liquid or solid,
evokes different impacts on gut microbiota and integrity,
thus differently affecting liver homeostasis [15]. In order to
counteract the growing burden of sugar-related chronic dis-
eases, innovative strategies, aimed to reduce caloric intake
and to replace conventional sugars with new low caloric
sweeteners, have garnered increasing attention. Among the
available alternative sugars, one of the most promising is
the D-tagatose, a peculiar sugar that is structurally similar
to D-fructose and has high palatability and a good sweeten-
ing property and is low in calories [16, 17]. This natural keto-
hexose is proved to be a potential replacement to sucrose-like
high-calorie bulk sweeteners as food additives, thanks to its
poor absorption and metabolization within the human body
[18]. Unlike fructose that has high glycation capacity and
promotes lipogenesis, D-tagatose has a lower glycation index
[19]. In human subjects, D-tagatose lowered postprandial
blood glucose and insulin response allegedly through inhibit-
ing intestinal disaccharides as like as glucose transport. In
addition, the results of a phase 3 clinical trial illustrated the
potential for D-tagatose, which effectively lowered HbA1c
levels in type 2 diabetic patients compared to placebo
[20–22]. Unfortunately, the molecular mechanisms underly-
ing health effects of the low caloric sugar D-tagatose have
hardly been investigated. To our knowledge, there is only
an in vivo study documenting the effects of D-tagatose on
obesity, hyperglycemia, and hypercholesterolemia in mice
[23]. So far, no experimental data are available comparing
D-tagatose with fructose, in terms of metabolic derange-
ments and related molecular mechanisms evoked by chronic
exposure to high levels of these two different carbohydrate
sources. Thus, the aim of this study was to determine if
and how D-tagatose alters lipid and sugar metabolism in
comparison to the results obtained with fructose, well known
for its glycative and lipogenic potential. Furthermore, since
we recently demonstrated that chronic feeding with fructose
contributes to evoke a maladaptive response in cardiac tissue
[24], we accordingly investigated the potential different
impacts of the two sugars on the heart, focusing mainly on
selective signaling pathways involved in the cardiometabolic
disease pathogenesis.
2. Materials and Methods
2.1. Animal Model and Procedures. Four-week-old male
C57Bl/6j mice (Charles River Laboratories, Calco, Italy, n =
30) were cared in conformity with the European Council
directives (No. 2010/63/EU) and with the Principles of Labo-
ratory Animal Care (NIH No. 85-23, revised 2011). The sci-
entific project was approved by the Ethical Committee of
Turin University and by the Italian Ministry of Health
(Authorization No. 1189/2016/PR). Mice, housed in a
temperature-controlled environment with a 12 h light/dark
cycle, were randomly allocated into the following dietary reg-
imens: a group fed a control diet and drinking tap water (CD
group, n = 6), a group fed a control diet and drinking a 30%
fructose syrup (L-Fr group, n = 6), a group fed with 30% fruc-
tose solid diet and drinking tap water (S-Fr group, n = 6), a
group fed a control diet and drinking a 30% D-tagatose syrup
(L-Tg group, n = 6), and a group fed with 30% D-tagatose
solid diet and drinking tap water (S-Tg group, n = 6) during
24 weeks. All groups received drink and food ad libitum.
All along the experimental protocol, body weight, glycemia,
and food intake were strictly monitored. One day before
euthanasia, urine of mice was collected for analysis by placing
animals in metabolic cages for 18 h.
Mice were anesthetized and killed by operating cardiac
exsanguination, so the blood was collected and the heart
was rapidly removed, frozen in liquid N2, and stored at
−80°C in order to carry out protein analysis.
2.2. Plasma and Urine Biochemical Analyses. A plasma lipid
profile (triglycerides [TGs], high-density lipoprotein [HDL],
and low-density lipoprotein [LDL]) was determined by stan-
dard enzymatic procedures using a reagent kit (Hospitex
Diagnostics, Florence, Italy). The concentration of plasma cre-
atinine was assessed by using commercial kits (Arbor Assays,
Ann Arbor, MI, USA).
HbA1C and proteinuria were measured in plasma
and urine, respectively, by using standard analysis kits. The
plasma leptin level and inflammatory profile (TNF-α, IL-
1β, and IL-6) were determined, as previously described [25]
using enzyme-linked immunosorbent assay (ELISA) kits.
2.3. Evaluation of Myocardial Oxidative Stress
2.3.1. Determination of Malondialdehyde (MDA). MDA was
determined by measurement of the chromogen obtained
from the reaction of MDA with 2-thiobarbituric acid. Briefly,
heart tissues were homogenized with 1ml of 50mM Tris-
HCl buffer containing 180mM KCl and 10mM EDTA, final
pH7.4. Then, 0.5ml of 2-thiobarbituric acid (1% w/v) in
50mM NaOH and 0.5ml of HCl (25% w/v in water) were
added to 0.5ml of sample. The mixture was placed in test
tubes, sealed with screw caps, and heated in boiling water
for 10min. After cooling, the chromogen was extracted in
3ml of 1-butanol, and the organic phase was separated by
centrifugation at 2000g for 10min. The absorbance of the
organic phase was read spectrophotometrically at a 532nm
wavelength. The values are expressed as nanomoles of thio-
barbituric acid-reactive substances (MDA equivalents) per
milligram of protein, using a standard curve of 1,1,3,3-
tetramethoxypropane.
2.3.2. Evaluation of Catalase (CAT). CAT activity was mea-
sured using the Calbiochem® Catalase Assay Kit (Merck
Millipore) following the instructions provided by the
manufacturer.
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2.3.3. Determination of 8-Hydroxy-2′-deoxyguanosine (8-
OHdG). DNA isolation from cardiac tissue homogenates
was performed according to Collino et al. [25, 26]. Samples
of DNA extract were used for 8-hydroxy-2′-deoxyguano-
sine (8-OHdG) determination using an ELISA kit (JalCA,
Shizuoka, Japan), following the instructions provided by the
manufacturer. The absorbance of the chromogenic product
was measured at 450 nm and expressed as ng/mg of DNA.
The results were calculated from a standard curve based on
8-OHdG solution. The values are expressed as ng 8-OHdG/
μg total DNA.
2.4. Protein Extraction and Western Blot. Cytosolic and
nuclear extracts from hearts were prepared as previously
described [27]. Succinctly, hearts were homogenized at 10%
(wt/vol) with a Potter Elvehjem homogenizer (Wheaton,
Millville, NJ) using a homogenization buffer containing
20mM HEPES (pH7.9), 1mM MgCl2, 0.5mM EDTA, 1%
Nonidet P-40, 1mM EGTA, 1mM DTT, 0.5mM PMSF,
and 1μl/ml of PIC. Homogenates were centrifuged at
1300g for 5min at 4°C. Supernatants were removed and cen-
trifuged at 16,000g at 4°C for 40min to obtain supernatant
containing the cytosolic fraction. The pelleted nuclei were
resuspended in extraction buffer (1/3 volume of the homoge-
nation buffer) containing 20mM HEPES (pH7.9), 1.5mM
MgCl2, 300mM NaCl, 0.2mM EDTA, 20% glycerol, 1mM
EGTA, 1mM DTT, 0.5mM PMSF, and 1μl/ml of PIC and
incubated in ice for 30min, followed by centrifugation at
16,000g for 20min at 4°C. The resulting supernatants con-
taining nuclear proteins were carefully removed. Protein
content was determined by the BCA assay, and extracts were
stored at −80°C until use. Semiquantitative immunoblot
analyses of the phosphorylation of IKKα/β and IκBα, nuclear
translocation of p65, expression of COX-2 and RAGE, and
CML- and CEL-glycated proteins were carried out in
mouse heart tissue extracts. About 60μg of proteins were
separated by SDS-PAGE and electrotransferred on a PVDF
membrane. After blocking (1 h in 5% dry milk solution),
membranes were incubated with primary antibodies (rabbit
anti-p65 NF-κB [1 : 1000], rabbit anti-IKKα/β [1 : 1000], rab-
bit anti-Ser176/180 IKKα/β [1 : 5000], mouse anti-IκBα
[1 : 1000], mouse anti-Ser32/36 IκBα [1: 1000], rabbit anti-
COX-2 [1 : 1000], goat anti-RAGE, [1 : 1000], mouse anti-
CML [1 : 500], and mouse anti-CEL [1 : 100]) followed by
incubation with appropriated HRP-conjugated secondary
antibodies. To ascertain that membranes were loaded with
equal amounts of cytosolic or nuclear proteins, they were
also incubated with antibody against tubulin or histone-
H3, respectively. Proteins were detected with an enhanced
chemiluminescent (ECL) detection system and quantified
by densitometry using an analytic software (Quantity-
One, Bio-Rad, Hercules, CA, USA). Results were normal-
ized with respect to densitometric value of the protein used
as loading control.
2.5. PgE2 Measurement. Tissue fragments were homogenized
at 0–4°C in the presence of 10μmol/liter indomethacin so as
to prevent PG production during the procedure, and then
they were centrifuged at 600g. Five hundred μl of tissue
homogenates were used for PgE2 determination using a com-
petitive enzyme immunoassay kit (Cayman Chemical Co.,
Ann Arbor, MI).
2.6. Statistics. All values are presented as mean± SEM for no.
observations. We analyzed data using the Prism software
package (GraphPad Software, San Diego, CA, USA). Com-
parisons among groups were performed using one-way
ANOVA with Bonferroni’s multiple comparison post hoc
test. Differences between groups were considered statistically
significant at p values below 0.05.
3. Results
3.1. Effects of Fructose- or D-Tagatose-Enriched Diets on
Metabolic Parameters. As shown in Table 1, chronic
exposure to Fr diet evoked a two-fold increase in body
weight gain, when compared to CD at 24 weeks of dietary
manipulation. In contrast, body weight gain recorded in
mice exposed to D-tagatose was similar to that recorded
in control mice.
After 24 weeks of dietary manipulation, L-Fr and S-Fr
mice showed a significant worsening in glycemic profile
(Table 1), with an increase in plasma fasting glucose and in
the percentage of HbA1c, if compared to CD- or D-
tagatose-fed mice. Similarly, L-Fr and S-Fr diets led to an
increase in plasma leptin concentration and in the levels of
Table 1: Effects of fructose and tagatose on systemic parameters at 24 weeks of dietary manipulation.
CD
(n = 6)
L-Fr
(n = 6)
S-Fr
(n = 6)
L-Tg
(n = 6)
S-Tg
(n = 6)
Glucose (nmol/l) 11.3± 0.7 15.1± 0.4∗∗§§ 14.6± 0.6∗∗§§ 11.0± 0.2 10.9± 0.9
HbA1c (%) 2.8± 0.1 5.5± 0.1∗∗§ 4.8± 0.2∗∗§ 3.13± 0.4 3.0± 0.3
Leptin (μg/ml) 2.4± 0.1 27.3± 0.7∗∗§ 17.7± 1.2∗∗§ 3.9± 0.8 5.1± 0.3
Triglycerides (mg/dl) 39.6± 3.9 64.8± 2.6∗∗§§ 63.7± 4.6∗∗§§ 38.7± 2.5 36.4± 3.6
HDL (mg/dl) 53.2± 5.6 34.7± 5.2∗∗§§ 35.6± 5.0∗∗§§ 44.7± 6.9 46.6± 3.4
LDL (mg/dl) 23.6± 2.4 36.5± 3.1∗∗§§ 34.2± 4.1∗∗§§ 29.6± 3.4 26.5± 5.2
Creatinine (mg/dl) 0.45± 0.06 1.15± 0.09∗∗§§ 0.90± 0.08∗∗ 0.68± 0.09 0.68± 0.07
Proteinuria (mg/24 hours) 6.13± 0.24 17.4± 0.33∗∗§§ 14.63± 0.54∗∗§§ 6.45± 0.42 6.60± 0.27
Body weight gain (g) 3.52± 0.26 6.00± 0.26∗∗§§ 6.32± 0.50∗∗§§ 2.64± 0.43 2.38± 0.27
Data are means ± S.E.M. ∗∗p < 0 01 vs. control diet §p < 0 05 vs. tagatose; §§p < 0 01 vs. tagatose.
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blood triglycerides and LDL; paralleled by a significant
decrease in HDL levels. Leptin and lipid profile were not
affected by L-Tg or S-Tg diets.
Fructose (both liquid and solid formulations), but not D-
tagatose, reduced kidney function, leading to a significant
increase in blood serum creatinine and proteinuria, when
compared to control mice.
3.2. Effects of Fructose- or D-Tagatose-Enriched Diets on
Markers of Systemic Inflammation. Chronic supplementa-
tion with either fructose or D-tagatose, both in liquid and
solid form, led to a significant increase in plasma levels
of TNF-α and IL-1β when compared to CD (Figure 1).
However, the increase in TNF-α and IL-1β evoked by D-
tagatose feeding reached values that were approximately
halved if compared to the levels obtained in the corre-
sponding fructose diet group. Interestingly, no effects of
D-tagatose on IL-6 plasma levels were recorded, whereas
fructose chronic exposure induced a three-fold increase
in this systemic inflammatory marker.
3.3. Effects of Fructose- or D-Tagatose-Enriched Diets on
Myocardial Markers of Oxidative Stress. Sugar-sweetened
diet can intensely contribute to the development of heart dis-
ease [28, 29] mainly increasing oxidative stress [30].
When measured in the hearts of mice fed a diet enriched
in liquid or solid fructose, the oxidative stress markers
(MDA, catalase, and 8-OHdG) were tripled compared to
those of the CD for both diet regimens, without significant
differences between the liquid or solid form (Figure 2). None
of these oxidative derangements was observed in the heart
tissue homogenates of D-tagatose-fed mice.
3.4. Effects of Fructose- or D-Tagatose-Enriched Diets on
Myocardial Activation of Inflammatory Pathways. Since the
results so far obtained did not show any significant difference
between the liquid and the solid administration regime, both
at the systemic or myocardial level, the evaluation of the
molecular mechanisms underlying the different effects of
fructose or D-tagatose administration on the heart was per-
formed in the two liquid groups only.
We investigated the effects of fructose or D-tagatose
supplementation on the signaling pathways involved in
the activation of NF-κB, as this transcriptional factor plays
a pivotal role in diet-induced inflammation. When compared
to CD-fed mice, we observed a significant increase in the
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Figure 1: Effects of chronic sugar exposure on systemic inflammatory profile. Plasma levels of TNF-α (a), IL-1β (b), and IL-6 (c) were
measured in mice fed for 24 weeks with a control diet or with a diet containing liquid or solid supplementation of fructose/D-tagatose.
Values are represented as means± S.E.M. of 6 animals per group. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001, vs. CD. ## and ### denote,
respectively, p < 0 01 and p < 0 001 vs. corresponding Tg formulation.
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phosphorylation of Ser176/180 on IKKα/β (Figures 3(a))
and Ser32/36 on IκBα (Figures 3(b)) and the nuclear trans-
location of the p65 NF-κB subunit (Figures 3(c)) in the
heart of fructose-fed mice. D-tagatose supplementation did
not significantly affect the phosphorylation of Ser176/180
on IKKα/β and Ser32/36 on IκBα nor the subsequent trans-
location of the p65 NF-κB subunit from the cytosol to the
nucleus (Figure 3).
The local excessive inflammatory response within the
heart of fructose-fed mice was further confirmed by the
detection of increased myocardial expression and activation
of the COX-2 enzyme isoform. In fact, when compared to
CD-fed mice, a significant increase in the expression of
COX-2 and release of PgE2 in the heart of fructose chroni-
cally fed mice was observed. D-tagatose supplementation
did not significantly affect COX-2 expression and activity
(Figure 4).
3.5. Effects of Fructose- or D-Tagatose-Enriched Diets on
Myocardial Activation of the AGE/RAGE Cascade. Advanced
Glycation End Products (AGEs) are toxic compounds deriv-
ing from nonenzymatic glycation reactions of reducing
sugars with proteins, which then result in becoming struc-
turally and functionally compromised. AGEs are known to
contribute to the development and/or progression of cardio-
vascular diseases, mainly through induction of oxidative
stress and inflammation. Here we measured local levels of
the most known AGEs carboxymethyllysine/carboxyethylly-
sine- (CML/CEL-) protein adducts, showing a massive over-
production in the group of mice fed fructose liquid
formulation (Figures 5(a) and 5(b)). As expected, the fructose
effects on myocardial accumulation of AGEs are parallel with
an almost three-fold increase in RAGE expression in the L-Fr
group when compared to CD mice (Figure 5(c)). Interest-
ingly, Western blot analysis demonstrated that D-tagatose
feeding was associated with a significantly lower AGE accu-
mulation and RAGE hyperexpression when compared to
those recorded in the L-Fr group.
4. Discussion
Our results confirm and further extend previous studies
demonstrating the damaging effects associated with chronic
exposure to high-fructose intake, leading to impairments of
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Figure 2: Effects of sugars feeding on myocardial markers of oxidative stress. Malondialdehyde (MDA; a), catalase (b), and 8-hydroxy-2′
-deoxyguanosine (8-OHdG; c) were measured in heart homogenates of mice fed for 24 weeks with a control diet or with a diet containing
liquid or solid supplementation of fructose/D-tagatose. Values are represented as means± S.E.M. of 6 animals per group. ∗∗ and ∗∗ ∗
denote, respectively, p < 0 01 and p < 0 001 vs. CD. ## and ### denote, respectively, p < 0 01 and p < 0 001 vs. corresponding Tg formulation.
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systemic glucose and lipid profiles as well as renal function.
Most notably, we documented that the metabolic abnormal-
ities caused by exposure to an unhealthy diet containing high
concentrations of fructose were not recorded when fructose
was replaced by D-tagatose, thus demonstrating that the pro-
posed change in nutrient composition favorably affected
metabolic homeostasis. Accordingly, D-tagatose had no
effect on body weight, whereas a diet containing an equiva-
lent amount of fructose resulted in significant body weight
gain at the end of the dietary manipulation. These findings
are in keeping with a previously published paper showing
that, in comparison to sucrose, a diet enriched in D-
tagatose as a carbohydrate source did not promote obesity,
hyperglycemia, or adipocyte hypertrophy and resulted in a
lesser extent of hypercholesterolemia and atherosclerosis,
when tested in low-density lipoprotein receptor-deficient
(LDLr−/−) mice [23]. Our study was designed to perform also
a comparative investigation on the toxicological impact of
different formulations (liquid versus solid forms) of the same
dietary component. Our data show no differences for sys-
temic metabolic and inflammatory parameters according to
the sugar format. Interestingly, the systemic inflammatory
profile recorded in the blood of D-tagatose-fed mice was far
less than that observed in fructose-fed mice. The excessive
systemic inflammation of fructose-fed mice may have signif-
icantly contributed to glucose and lipid dysregulation, with
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Figure 3: Effects of liquid sugars feeding on myocardial activation of the NF-κB pathway. Representative Western blotting and relative
densitometric analysis of the activation of the NF-κB pathway measured as phosphorylation of IKKα/β at Ser176/180 (a), phosphorylation
of IκBα at Ser32/36 (b), and nuclear translocation of p65 subunit of NF-κB (c) in the heart of mice fed for 24 weeks with a control diet or
with a diet containing liquid supplementation of fructose/D-tagatose. Protein expression was measured as relative optical density (OD),
corrected for the corresponding tubulin or histone H3 contents and normalized using the related CD band. Values are represented as
means± S.E.M. of 6 animals per group. ∗∗ ∗ denotes p < 0 001 vs. CD. ## denotes p < 0 01 vs. L-Tg diet.
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the role of a low-grade, chronic inflammatory response,
known as metaflammation, in promoting metabolic diseases
being well described [31]. In contrast, the limited inflamma-
tory profile in D-tagatose-fed mice is suggestive, at least in
part, of a reduced secretion of inflammatory mediators by
obese visceral fat, thanks to the D-tagatose ability to
counteract mice weight gain. Experimental evidence sup-
ports a role for components of the diet, including sugar-
sweetened beverages, in the development of heart disease
[28, 29]. As confirmed by several epidemiological studies in
diabetic patients, cardiovascular complications represent
the principal cause of morbidity and mortality. The mecha-
nisms of diabetic cardiomyopathy are multifaceted, involving
increased oxidative/nitrosative stress, accumulation of AGEs,
activation of various proinflammatory, and cell death sig-
naling pathways [30]. Myocardial inflammation has been
reported as one of the main driving forces in the patho-
genesis of cardiac dysfunction, and notably, the linkage of
metabolic cardiomyopathy with inflammation has incited
research into new effective treatments for diastolic dysfunc-
tion of obesity and insulin resistance [32]. We have recently
contributed to demonstrate a correlation between increased
activity of selective inflammatory pathways, due to chronic
high-fructose feeding, and enhanced susceptibility to a myo-
cardial ischemic insult [24]. Interestingly, the circulating
levels of the soluble receptor of AGEs (sRAGE) have been
suggested to be a valuable predictor of cardiovascular dis-
eases, being sRAGE concentrations elevated after myocar-
dial infarction [33] and associated with poor in-hospital
prognosis [34]. In keeping with these previous findings, we
report here that fructose feeding resulted in overexpression
of both AGEs and the chief AGE receptor RAGE in the myo-
cardial tissue. Most notably, we offered, for the first time, the
experimental evidence of the lower chemical reactivity of D-
tagatose when compared to its epimer fructose, resulting in a
dramatic decrease in the in vivo formation of AGEs and
expression of RAGE. Thus, we can state that slight differ-
ences in the position of the hydroxyl group at carbon atom
4 may result in significant differences in sugar reactivity
and sugar metabolism. Recent findings show that fructose
produces 10 times more AGEs than glucose because the
anomerization equilibrium for fructose is shifted more to
the reactive, open chain form of the sugar [35]. Even though
our study did not deepen the chemical characterization and
quantification of the specific structures of sugar-induced pro-
tein glycation products, it is, to our knowledge, the first
experimental comparative evidence of mechanistic differ-
ences associated with chronic exposure to two ketohexose
stereoisomeric sugars. Oxidative stress is a key factor in the
pathophysiology of diet-related cardiovascular complications
[36, 37]. Very recently, RAGE activation, following binding
with AGEs, has been shown to mediate oxidative stress in
cardiomyocytes [38]. Here we confirmed that mice exposed
to fructose, in both the liquid and solid formulations, exhib-
ited a massive increase in myocardial oxidative stress, as sug-
gested by markers of peroxidation of cell membrane lipids
and radical-induced DNA damage as well as activity of anti-
oxidant enzymes. The lack of any effects on the measured
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Figure 4: Effects of liquid sugars feeding on myocardial expression and activation of COX-2. Representative Western blotting and relative
densitometric analysis of the expression of COX-2 (a) and concentration of PgE2 (b) in the heart of mice fed for 24 weeks with a control diet
or with a diet containing liquid supplementation of fructose/D-tagatose. Protein expression was measured as relative optical density (OD),
corrected for the corresponding tubulin contents and normalized using the related CD band. Values are represented as means± S.E.M. of 6
animals per group. ∗∗ and ∗∗ ∗ denote, respectively, p < 0 01 and p < 0 001 vs. CD. ## and ### denote, respectively, p < 0 01 and p < 0 001
vs. L-Tg diet.
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markers of oxidative stress by both solid and liquid formula-
tion of D-tagatose further corroborate the evidence of
reduced activation of the AGE/RAGE-dependent pathways.
The activation of the AGE/RAGE signaling is known to be
associated not only with increased oxidative stress but also
with a proinflammatory state, due mainly to the activation
and nuclear translocation of the NF-κB transcription factor
[39]. As recently documented in an elegant in vivo study
[40], ingestion of AGE-enriched food resulted in a rapid acti-
vation of NF-κB in the heart, via a direct interaction with
RAGE, reaching the highest myocardial NF-κB activity 12 h
after AGE feeding. As reported here, fructose, but not D-
tagatose, feeding evoked a massive activation of the IKK
complex and the related degradation of IκBα, thereby liberat-
ing NF-κB, resulting in NF-κB translocation to the nucleus.
Long-term activation of the proinflammatory NF-κB may
account for the increased expression and activity of COX-2
recorded in the homogenates of hearts from fructose-fed
mice. The role of COX-2 in heart function and pathology
has been widely explored in the last few years, mainly due
to the finding that specific COX-2 inhibitors significantly
increased the risk of heart disease in chronic users [41]. Both
elevated expression of COX-2 in cardiomyocytes and local
concentrations of prostaglandins have been associated with
human heart disease, particularly heart failure [42, 43]. Of
course, such studies are quite inconclusive, as the recorded
increases could be secondary effects due to the heart failure,
as opposed to an ongoing mechanism of pathology. How-
ever, they overall suggest that impairments in COX-2 expres-
sion and activity may be associated with the development of
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Figure 5: Effects of liquid sugars feeding on myocardial accumulation of AGE and expression of RAGE. Representative Western blotting and
relative densitometric analysis of CEL- and CML-glycated proteins (a and b, respectively) and RAGE expression (c) in the heart of mice fed
for 24 weeks with a control diet or with a diet containing liquid supplementation of fructose/D-tagatose. Protein expression was measured as
relative optical density (OD), corrected for the corresponding tubulin contents and normalized using the related CD band. Values are
represented as means± S.E.M. of 6 animals per group. ∗∗ denotes p < 0 01 vs. CD. # denotes p < 0 05 vs. L-Tg diet.
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heart diseases. Thus, the experimental evidence of nonsignif-
icant modulation of both markers of oxidative stress and
excessive inflammatory response in the heart of mice chron-
ically fed D-tagatose is suggestive of reduced potential car-
diac toxicity when D-tagatose is used as a sugar substitute.
The experimental model proposed here allows us to perform
a comparative study, in a strictly controlled environment, on
the intrinsic capacity of two fructose epimers to affect an
early marker of myocardial injury and dysfunction. However,
we are aware of some limitations of the present study, includ-
ing the lack of pharmacokinetics, hemodynamic and func-
tional data, and the impossibility to dissect between the
redox and inflammatory effects related to sugar exposure.
Our study does not allow identifying the specific cell types
involved in sugar-mediated responses. Cardiomyocytes are
the most prominent cell type in the heart, and loss of
contractile tissue is the most important consequence of a
myocardial dysfunction. However, dysregulation of cardiac
fibroblast function may also contribute to adverse cardiac
remodeling and eventually heart failure, and AGEs have
been demonstrated to induce cardiac fibroblast proliferation
by interfering with the AGE/RAGE pathway [44]. Besides,
as D-tagatose is partially fermented in the large intestine
[45, 46], we cannot rule out that differences in absorption
of the two fructose epimers may affect, at least in part, their
different toxicological profiles. Thus, future ad hoc studies
are required to clarify these aspects.
In conclusion, to the best of our knowledge, this is the
first study that analyzes from a comparative point of view
the consequences of chronic oral administration of fructose
or its naturally occurring epimer, D-tagatose, in a nongenetic
model of diet-induced metabolic derangements. Our data
demonstrate significant qualitative and quantitative sugar-
dependent differences in early markers of organ injury, due
to selective interference of fructose with the AGE/RAGE cas-
cade, not recorded when mice were fed with D-tagatose.
Thanks to its very low caloric value and organoleptic similar-
ities with fructose, the rare sugar D-tagatose may represent a
safer paradigm of sweeteners with limited toxicological
impact on obesity and associated metabolic disorders. Fur-
ther preclinical and clinical studies are needed to better
explore this possibility and to investigate/ensure the safety
of this innovative approach.
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